5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 601–700 of 1,028
Antineoplastic Agents: Environmental Prevalence and Adverse Outcomes in Aquatic Organisms
Wormington, A. M., María, M. D., Kurita-Oyamada, H. G., Bisesi, J. H., Denslow, N. D., & Martyniuk, C. J. (2020) · Environmental Toxicology and Chemistry · doi:10.1002/etc.4687 · Cited by 76
“Antimetabolites inhibit the formation of essential biomolecules such as DNA, RNA, and proteins, preventing the growth and division of cancer cells (Longley et al. 2003).”
InfluentialBronckaers, A., Balzarini, J. M., & Liekens, S. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.04.019 · Cited by 77
Abaci, H. E., Shen, Y.-I., Tan, S., & Gerecht, S. (2014) · Scientific Reports · doi:10.1038/srep04951 · Cited by 71
Exploiting DNA mismatch repair deficiency as a therapeutic strategy
Guillotin, D., & Martin, S. A. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.07.004 · Cited by 78
Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma
Dai, W., Gao, Q., Qiu, J., Yuan, J., Wu, G., & Shen, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-4501-0 · Cited by 72
“On the contrary, Bad and Bax are the important proapoptotic proteins by changing the mitochondrial membrane potential and activating the Caspase family and eventually lead to cell apoptosis [4, 16].”
BackgroundInfluentialPan, Y., Wang, S., He, X., Tang, W., Wang, J., Shao, A., & Zhang, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01651a · Cited by 72
Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer
Liang, Y., Li, Y., Song, X., Zhang, N., Sang, Y., Zhang, H., Liu, Y., Chen, B., Zhao, W., Wang, L., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1394543 · Cited by 71
FICC-Seq: a method for enzyme-specified profiling of methyl-5-uridine in cellular RNA
Carter, J.-M., Emmett, W., Mozos, I. R. D. L., Kötter, A., Helm, M., Ule, J., & Hussain, S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz658 · Cited by 76
“For example, it has been shown that in addition to inhibition of thymidylate synthase, uncharacterized RNA-mediated pathways very likely also play significant roles in the cytotoxic mechanism of 5FU (40,41).”
BackgroundTherapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review)
Ji, Y., Lv, J., Sun, D., & Huang, Y. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5056 · Cited by 78
Gomes, S., Rodrigues, A., Pazienza, V., & Preto, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065069 · Cited by 83
“OX is a platinumbased chemotherapy drug that damages the DNA in cancer cells, which slows their growth and division [10].”
BackgroundInfluentialAntivitamins for Medicinal Applications
Zelder, F., Sonnay, M., & Prieto, L. (2015) · ChemBioChem · doi:10.1002/cbic.201500072 · Cited by 73
Zhang, G., Moore, D. J., Sloan, K. B., Flach, C. R., & Mendelsohn, R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700690 · Cited by 71
“5-Fluorouracil (5FU), an important systemic antitumor drug (Longley et al., 2003), is also used to treat cancerous or precancerous conditions in skin including solar keratoses, actinic keratosis, superficial basal cell carcinoma, and Bowen’s disease.”
BackgroundShin, Y., Yoo, B. C., Hong, Y. S., Chang, H. J., Jung, K. H., Jeong, S., & Park, J. (2009) · Electrophoresis · doi:10.1002/elps.200800806 · Cited by 78
Gennaro, E. D., Bruzzese, F., Pepe, S., Leone, A., Delrio, P., Subbarayan, P. R., Avallone, A., & Budillon, A. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.9.8118 · Cited by 72
Ichikawa, W., Takahashi, T., Suto, K., Sasaki, Y., & Hirayama, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2665 · Cited by 71
“FUMP is then phosphorylated to fluorouridine diphosphate, which can be either converted to FdUMP or phosphorylated to the active metabolite fluorouridine triphosphate (3).”
BackgroundInfluentialPrecision targeted therapy of ovarian cancer
Sapiezynski, J., Taratula, O., Rodríguez-Rodríguez, L., & Minko, T. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.014 · Cited by 81
“Fluorouracil-5 is a pyrimidine analog that acts as a suicide inhibitor by irreversibly binding to the thymidylate synthase enzyme [117].”
BackgroundFluoropyrimidine-induced cardiotoxicity
Depetris, I., Marino, D., Bonzano, A., Cagnazzo, C., Filippi, R., Aglietta, M., & Leone, F. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.02.002 · Cited by 71
Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response
Nies, A. T., Magdy, T., Schwab, M. G., & Zanger, U. M. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.10.007 · Cited by 87
Inhibition of p53-mediated transcriptional responses by mithramycin A
Koutsodontis, G., & Kardassis, D. (2004) · Oncogene · doi:10.1038/sj.onc.1208141 · Cited by 71
“5-FU is frequently used in the treatment of a wide range of cancers, including colorectal and breast cancers, and cancers of the aerodigestive tract (Longley et al., 2003).”
BackgroundThe Evolution of the Ribosomal Protein–MDM2–p53 Pathway
Deisenroth, C., Franklin, D. A., & Zhang, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026138 · Cited by 76
“One example is the metabolite of 5-fluorouracil, 5-fluorouridine triphosphate, which misincorporates as a uracil substitution and has been identified to enhance the association of RPL5, RPL11, and RPL23 with MDM2 to activate p53 (Longley et al. 2003; Sun et al. 2007).”
BackgroundAnwar, M., Pervaiz, F., Shoukat, H., Noreen, S., Shabbir, K., Majeed, A., & Ijaz, S. (2020) · Polymer Bulletin · doi:10.1007/s00289-019-03092-4 · Cited by 76
Gami, P., Kundu, D., Seera, S. D. K., & Banerjee, T. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.04.237 · Cited by 72
Chen, H., Pei, L., Xie, P., & Guo, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s253468 · Cited by 74
“Keywords: CRC, 5-FU, circ-PRKDC, miR-375, FOXM1, wnt/β-catenin Introduction Colorectal cancer (CRC) is a malignant tumor with high morbidity and mortality, seriously threatening human health.1,2 Conventional treatment strategy for CRC patients is surgery combined with chemotherapy.3 5-fluorouracil (5-FU) is the basis…”
BackgroundInfluentialZhou, X., Fu, L., Wang, P., Yang, L., Zhu, X., & Li, C. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111445 · Cited by 70
Mengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Berihun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03558-0 · Cited by 85
Wei, J., Zou, Z., Qian, X., Ding, Y., Xie, L., Sánchez, J. J., Zhao, Y., Feng, J., Ling, Y., Liu, Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604317 · Cited by 73
“Considerable published evidence suggests that interindividual variation in response to 5-FU results from variations in the thymidylate synthase (TS) mRNA expression levels of the tumour (Longley et al, 2003).”
BackgroundHead and neck cancer stem cells: The side population
Tabor, M. H., Clay, M. R., Owen, J. H. J., Bradford, C. R., Carey, T. E., Wolf, G. T., & Prince, M. E. P. (2010) · The Laryngoscope · doi:10.1002/lary.21032 · Cited by 74
“lites into RNA and DNA, inhibiting DNA synthesis and inducing cell death.(43) The drug targets cycling cells that”
BackgroundZhang, J., Wu, J., Li, H., Chen, Q., & Lin, J. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.01.013 · Cited by 73
“In liver cells most 5-FU is converted into nontoxic metabolite so it has little influence on liver cells(Longley et al., 2003).”
BackgroundERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer
Kim, M. K., Cho, K.-J., Kwon, G. Y., Park, S.-I., Kim, Y., Kim, J. H., Song, H.-Y., Shin, J. H., Jung, H., Lee, G. H., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.09.006 · Cited by 70
Kadoyama, K., Miki, I., Tamura, T., Brown, J. B., Sakaeda, T., & Okuno, Y. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.9.33 · Cited by 82
“tumors for nearly 50 years [1].”
Sağır, T., Huysal, M., Durmuş, Z., Kurt, B. Z., Şenel, M., & Işık, S. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.025 · Cited by 71
FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10
Xie, T., Geng, J., Wang, Y., Wang, L., Huang, M., Chen, J., Zhang, K., Xue, L., Liu, X., Mao, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14351 · Cited by 70
“Fluorouracil-based chemotherapy is the most common chemotherapy for CRC patients with unresectable or metastatic tumors [33].”
Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
Coyle, K. M., Boudreau, J. E., & Marcato, P. (2017) · BioMed Research International · doi:10.1155/2017/9620870 · Cited by 84
Kato, S., Hamouda, N., Kano, Y., Oikawa, Y., Tanaka, Y., Matsumoto, K., Amagase, K., & Shimakawa, M. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12792 · Cited by 74
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
Scartozzi, M., Galizia, G., Freddari, F., Berardi, R., Cellerino, R., & Cascinu, S. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.01.001 · Cited by 71
Liu, X., Xie, T., Mao, X., Xue, L., Chu, X., & Chen, L. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445653 · Cited by 69
5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer
Du, C., Huang, D., Peng, Y., Yao, Y., Zhao, Y., Yang, Y., Wang, H., Cao, L., Zhu, W., & Gu, J. F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.033 · Cited by 70
Vaginal drug delivery for the localised treatment of cervical cancer
Major, I., & McConville, C. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0395-2 · Cited by 70
“b i t ion of the thymidyla te synthase enzyme and misincorporation into DNA and RNA [58].”
BackgroundFuplatin: An Efficient and Low-Toxic Dual-Prodrug
Zhang, R., Song, X., Liu, R.-P., Ma, Z., & Xu, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00128 · Cited by 74
Sharma, P. C., Sharma, D., Sharma, A., Bansal, K. K., Rajak, H., Sharma, S., & Thakur, V. K. (2020) · Applied Materials Today · doi:10.1016/j.apmt.2020.100783 · Cited by 71
5-Fluorouracil, innovative drug delivery systems to enhance bioavailability for topical use
de Oliveira, B. E., Amorim, O. H. J., Lima, L. L., Rezende, R. A., Mestnik, N. C., Bagatin, E., & Leonardi, G. R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102155 · Cited by 70
Animal models of chemotherapy-induced cognitive decline in preclinical drug development
John, J., Kinra, M., Mudgal, J., Viswanatha, G. L., & Nandakumar, K. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05977-7 · Cited by 67
Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation
Huo, Z., Liu, K., Wang, Z., Wang, S.-J., Liu, P., Qin, Y., Ma, Y., & Li, X. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s89476 · Cited by 78
“Therefore, it is utmost necessary to develop a nano drug delivery system to increase the therapeutic performance of 5-FU.(9,10) To overcome the aforementioned limitations, a number of polymer-based drug”
Anderson, B. G., Parker, J. B., Guminski, A. F., & Stivers, J. T. (2010) · Biochemistry · doi:10.1021/bi102046h · Cited by 71
“However, an additional hallmark of fluoropyrimidine treatment is the polymerase catalyzed incorporation of dUMP and 5-F-dUMP into DNA resulting in U/A, 5-FU/A and 5-FU/G base pairs which are substrates for various uracil DNA repair glycosylases (1,4,5).”
BackgroundKuo, Y., Lin, H.-P., Huo, C., Su, L., Yang, J., Hsiao, P.-H., Chiang, H.-C., Chung, C., Wang, H., Chang, J., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14058801 · Cited by 71
“5-fluorouracil suppresses cancer cells by misincorporating fluoronucleotides into RNA and DNA as well as by inhibiting the nucleotide synthetic enzyme thymidylate synthase [44].”
BackgroundShi, B. J., Nie, X., Chen, L., Liu, Y., & Tao, W. (2006) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2006.08.003 · Cited by 69
Millino, C., Maretto, I., Pacchioni, B., Digito, M., Paoli, A. D., Canzonieri, V., D’Angelo, E., Agostini, M., Rizzolio, F., Giordano, A., et al. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25441 · Cited by 75
Lima, D., Calaça, G. N., Viana, A. G., & Pessôa, C. A. (2017) · Applied Surface Science · doi:10.1016/j.apsusc.2017.08.228 · Cited by 69
Milczarek, M., Wiktorska, K., Mielczarek, L., Koronkiewicz, M., Dąbrowska, A., Lubelska, K., Matosiuk, D., & Chilmończyk, Z. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.10.056 · Cited by 70
Li, H., Su, L., Chen, S., Zhao, L., Wang, H., Ding, F., Chen, H., Shi, R., Wang, Y., & Huang, Z. (2018) · Molecules · doi:10.3390/molecules23020508 · Cited by 76
“0 mg/mL, the inhibition against A549, HepG2, PC3, MCF-7, and Jurkat cells was 42%, 24%, 20%, 27% and 36%, respectively, at a comparable inhibition level with 100 μg/mL of 5-fluoro-2′-deoxyuridine (5-FUDR), an anti-metabolite drug that is widely used for cancer therapy [49].”
BackgroundNi, W., Li, Z., Liu, Z., Ji, Y., Wu, L., Sun, S., Jian, X., & Gao, X. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.042 · Cited by 70
Seera, S. D. K., Kundu, D., & Banerjee, T. (2020) · Cellulose · doi:10.1007/s10570-020-03249-9 · Cited by 73
Ciaffaglione, V., Modica, M. N., Pittalà, V., Romeo, G., Salerno, L., & Intagliata, S. (2021) · ChemMedChem · doi:10.1002/cmdc.202100473 · Cited by 78
Li, S., Ming, Y., Xu, H., Zhang, X., Mao, T., Quan, M., Ma, J., Wang, Y., Ge, W., Wang, Y., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216206 · Cited by 71
Yi, X., Hur, H., Ham, I., Yun, J., Lee, J.-Y., Shim, W., Kim, Y. B., Lee, G., Han, S., & Cho, Y. K. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.12.009 · Cited by 78
“[9] D.”
Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization
Basnet, H., Tian, L. H., Ganesh, K., Huang, Y.-H., Macalinao, D. G., Brogi, E., Finley, L. W. S., & Massagué, J. (2019) · eLife · doi:10.7554/elife.43627 · Cited by 78
“Although 5-FU or the combination of CD expression and 5-FC treatment are cytotoxic in some cells (Austin and Huber, 1993; Kievit et al., 1999; Longley et al., 2003), such toxicity requires more than 7 days of treatment (Hamstra et al.”
BackgroundAcute and sub-chronic toxicity of four cytostatic drugs in zebrafish
Kovács, R., Bakos, K., Urbányi, B., Kövesi, J., Gazsi, G., Csepeli, A., Appl, Á. J., Bencsik, D., Csenki, Z., & Horváth, Á. (2015) · Environmental Science and Pollution Research · doi:10.1007/s11356-015-5036-z · Cited by 68
Pascoalino, B. S., Courtemanche, G., Cordeiro, M. T., Gil, L. H. V. G., & Freitas-Junior, L. H. (2016) · F1000Research · doi:10.12688/f1000research.9648.1 · Cited by 68
Role of Anillin in Tumour: From a Prognostic Biomarker to a Novel Target
Nguyen, T. M., & Lee, C. H. (2020) · Cancers · doi:10.3390/cancers12061600 · Cited by 71
The effect of miRNA and autophagy on colorectal cancer
Long, J., He, Q., Yin, Y., Lei, X., Li, Z., & Zhu, W. (2020) · Cell Proliferation · doi:10.1111/cpr.12900 · Cited by 69
Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere
Campelj, D. G., Goodman, C. A., & Rybalka, E. (2021) · Cancers · doi:10.3390/cancers13143615 · Cited by 77
“This leads to both DNA and RNA damage and cell cycle arrest [93].”
BackgroundInfluentialLi, G., Fang, S., Shao, X., Li, Y., Tong, Q., Kong, B., Chen, L., Wang, Y., Yang, J. J., Yu, H., et al. (2021) · Biomolecules · doi:10.3390/biom11091295 · Cited by 67
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Ogunwale, G. J., Louis, H., Unimuke, T. O., Mathias, G. E., Owen, A. E., Edet, H. O., Enudi, O. C., Oluwasanmi, E. E., Adeyinka, A. S., & Mohammadi, M. D. (2023) · ACS Omega · doi:10.1021/acsomega.2c03635 · Cited by 69
The cubosome-based nanoplatforms in cancer therapy: Seeking new paradigms for cancer theranostics
Gowda, B. H. J., Ahmed, M. G., Alshehri, S. A., Wahab, S., Vora, L. K., Thakur, R. R. S., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116894 · Cited by 74
Díaz, T., Tejero, R., Moreno, I., Ferrer, G., Cordeiro, A., Artells, R., Navarro, A., Hernandez, R., Tapia, G., & Monzó, M. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23572 · Cited by 72
“5‐FU is an analog of uracil which once inside the cell contributes to the disruption of RNA synthesis and thymidine synthase action, leading to a decrease in cell proliferation [32].”
BackgroundVazquez-Martin, A., Ropero, S., Brunet, J., Colomer, R., & Menéndez, J. A. (2007) · Oncology Reports · doi:10.3892/or.18.4.973 · Cited by 67
5-Fluorouracil Pharmacogenomics: Still Rocking after all these years?
Scartozzi, M., Maccaroni, E., Giampieri, R., Pistelli, M., Bittoni, A., Prete, M. D., Berardi, R., & Cascinu, S. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.167 · Cited by 73
Chang, S. W., Lewis, A. R., Prosser, K. E., Thompson, J. R., Gladkikh, M., Bally, M. B., Warren, J. J., & Walsby, C. J. (2016) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6b00359 · Cited by 67
Saber, A., Alipour, B., Faghfoori, Z., & Khosroushahi, A. Y. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.05.007 · Cited by 72
Gelen, V., Şengül, E., Yıldırım, S., & Atila, G. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2018.27510.6714 · Cited by 67
Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells
Solier, S., Lansiaux, A., Logette, E., Wu, J. Y., Soret, J., Tazi, J., Bailly, C., Desoche, L., Solary, É., & Corcos, L. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.53.2.1 · Cited by 67
Ocker, M., Alajati, A., Ganslmayer, M., Zopf, S., L�ders, M., Neureiter, D., Hahn, E. G., Schuppan, D., & Herold, C. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0664-6 · Cited by 75
“As more than 80% of administered 5-FU is metabolized in the liver, the compound was expected to be highly effective in liver tumors (Longley et al. 2003; Diasia and Harris 1989).”
BackgroundKosovec, J. E., Egorin, M. J., Gjurich, S., & Beumer, J. H. (2007) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3362 · Cited by 67
A Common Telomeric Gene Silencing Assay Is Affected by Nucleotide Metabolism
Rossmann, M. P., Luo, W., Tsaponina, O., Chabes, A., & Stillman, B. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.007 · Cited by 79
“5-FdUMP forms a covalent complex with Cdc21 and the methyl donor methylenetetrahydrofolate, blocking the enzymatic methylation reaction of dUMP to dTMP (Figure 4C; Hardman et al., 2001; Jones and Fink, 1982; Longley et al., 2003).”
TOR coordinates nucleotide availability with ribosome biogenesis in plants
Busche, M., Scarpin, M. R., Hnasko, R. M., & Brunkard, J. O. (2021) · The Plant Cell · doi:10.1093/plcell/koab043 · Cited by 72
Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression
Choi, S., & Ku, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.060 · Cited by 72
Stevenson, L., Allen, W. L., Turkington, R., Jithesh, P. V., Proutski, I., Stewart, G., Lenz, H.-J., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1780 · Cited by 66
“Known determinants of 5-FU response include expression levels of TS and the 5-FU catabolic enzyme dihydropyrimidine dehydrogenase (DPD) which mediates the degradation of 5-FU (4).”
InfluentialSelf-citationThymidylate Kinase: An Old Topic Brings New Perspectives
Cui, Q., Shin, W. S., Luo, Y., Tian, J., Cui, H., & Yin, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320100006 · Cited by 66
Taddia, L., D’Arca, D., Ferrari, S., Marraccini, C., Severi, L., Ponterini, G., Assaraf, Y. G., Marverti, G., & Costi, M. P. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.003 · Cited by 66
Muliaditan, T., Opzoomer, J. W., Caron, J., Okesola, M., Kosti, P., Lall, S. K., Hemelrijck, M. V., Dazzi, F., Tutt, A. N. J., Grigoriadis, A. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2587 · Cited by 70
“Treatment with 5-FU, a chemotherapeutic which has been used in the clinic (38), and which has been demonstrated to stimulate an antitumor immune response (39, 40), also did not affect tumor growth as a single agent (Fig.”
BackgroundYe, F., Gao, Y., Wang, D., Xu, Z., Sun, W., & Ren, P. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2716-x · Cited by 66
Engineering tumor vasculature on an injection-molded plastic array 3D culture (IMPACT) platform
Lee, S., Lim, J., Yu, J., Ahn, J., Lee, Y., & Jeon, N. L. (2019) · Lab on a Chip · doi:10.1039/c9lc00148d · Cited by 65
5-Fluorouracil—Complete Insight into Its Neutral and Ionised Forms
Wielińska, J., Nowacki, A., & Liberek, B. (2019) · Molecules · doi:10.3390/molecules24203683 · Cited by 69
“It is an analogue of natural thymine and has been proven useful in the chemotherapy of different cancers [4].”
BackgroundNajafi, M., Mortezaee, K., Rahimifard, M., Farhood, B., & Haghi‐Aminjan, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118051 · Cited by 66
Probiotic‑derived ferrichrome inhibits the growth of refractory pancreatic cancer cells
Kita, A., Fujiya, M., Konishi, H., Tanaka, H., Kashima, S., Iwama, T., Ijiri, M., Murakami, Y., Takauji, S., Goto, T., et al. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5096 · Cited by 73
“In cancer cells, 5-FU is known to bind to thymidylate synthase, inhibit DNA synthesis and thereby inhibit progression to the S phase (38).”
BackgroundChemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine
Gmeiner, W. H. (2020) · Molecules · doi:10.3390/molecules25153438 · Cited by 66
“Considerable evidence indicates TS inhibition and perturbation of DNA-mediated processes is primarily responsible for the anti-cancer activity of FPs [10,41].”
BackgroundA second Warburg‐like effect in cancer metabolism: The metabolic shift of glutamine‐derived nitrogen
Kodama, M., & Nakayama, K. I. (2020) · BioEssays · doi:10.1002/bies.202000169 · Cited by 73
Application of smart nanoparticles as a potential platform for effective colorectal cancer therapy
Iranpour, S., Bahrami, A. R., Saljooghi, A. S., & Matin, M. M. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213949 · Cited by 70
miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers
El‐Mahdy, H. A., Sallam, A.-A. M., Ismail, A., Elkhawaga, S. Y., Elrebehy, M. A., & Doghish, A. S. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153886 · Cited by 66
Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer
Murillo, D., Huergo, C., Gallego, B., Rodríguez, R., & Tornín, J. (2023) · Biomedicines · doi:10.3390/biomedicines11010208 · Cited by 69
Application of aptamer-drug delivery system in the therapy of breast cancer
Fan, R., Tao, X., Zhai, X., Zhu, Y., Li, Y., Chen, Y., Dong, D., Yang, S., & Lv, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114444 · Cited by 74
Macleod, K. F. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2504 · Cited by 73
Popat, S., Chen, Z., Zhao, D., Pan, H., Hearle, N., Chandler, I. R., Shao, Y., Aherne, W., & Houlston, R. S. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl301 · Cited by 69
“TS is a ratelimiting enzyme involved in DNA synthesis [16], and competitive inhibition of its activity appears to be the major mechanism for the antitumour effect of fluoropyrimidines [17], the cornerstone of therapy for CRC.”
BackgroundManagement of stage IV rectal cancer: Palliative options
Ronnekleiv‐Kelly, S. M., & Kennedy, G. D. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i7.835 · Cited by 73
SenGupta, T., Torgersen, M. L., Kassahun, H., Vellai, T., Simonsen, A., & Nilsen, H. (2013) · Nature Communications · doi:10.1038/ncomms3674 · Cited by 66
Tumor Cells Require Thymidylate Kinase to Prevent dUTP Incorporation during DNA Repair
Hu, C.-M., Yeh, M.-T., Tsao, N., Chen, C., Gao, Q.-Z., Chang, C.-Y., Lee, M.-H., Fang, J., Sheu, S., Lin, C.-J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.038 · Cited by 69
“For example, the thymidylate synthase inhibitors 5-FU and 5-FdUrd block the conversion of dUMP to dTMP, causing dUTP to accumulate and inducing the formation of 5-FdUTP (Longley et al., 2003).”
Ehsaan, M., Kuit, W., Zhang, Y., Cartman, S. T., Heap, J. T., Winzer, K., & Minton, N. P. (2016) · Biotechnology for Biofuels · doi:10.1186/s13068-015-0410-0 · Cited by 89
“acetobutylicum ATCC 824 genome contains a cluster of genes involved in the glycogen formation (CA_C 2237- CA_C 2239), that includes CA_C2239 (glgA) predicted to encode a glycogen synthase responsible for the formation of alpha-1,4-glucan chains from ADP-glucose [29].”
BackgroundInfluentialCell cycle perturbation and acquired 5-fluorouracil chemoresistance.
Guo, X., Goessl, E., Jin, G., Collie-Duguid, E. S. R., Cassidy, J., Wang, W., & O’Brien, V. (2008) · PubMed · Cited by 65
Liu, M.-P., Liao, M., Dai, C., Chen, J.-F., Yang, C., Liu, M., Chen, Z., & Yao, M. (2016) · Scientific Reports · doi:10.1038/srep34245 · Cited by 73
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.